3/25/2013

APO-T secured exclusive rights to develop and market LinXis' antibody-drug conjugates. The partners will combine APO-T's MAGE-HLA targeted antibodies and LinXis' linking platform. APO-T agreed to pay LinXis potential milestone fees and royalties.

Related Summaries